Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway.

doi:10.1016/j.phymed.2022.154523

科研成果详情

题名	Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway.
作者	Ye, Bozhi1; Chen, Xudong 2; Chen, Yanghao1; Lin, Wante 1; Xu, Diyun 1; Fang, Zimin1; Chattipakorn, Nipon 3; Huang, Weijian4; Wang, Xu 5; Wu, Gaojun6; Liang, Guang7
发表日期	2022-10-24
发表期刊	Phytomedicine : international journal of phytotherapy and phytopharmacology 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Costunolide Inflammation NF-κB Signaling Pathway Obesity Cardiomyopathy TAK1/TAB2 Complex
摘要	Chronic and persistent obesity can lead to various complications, including obesity cardiomyopathy. Inhibition of the inflammatory response is an effective measure for the intervention of obesity cardiomyopathy. Numerous studies indicate that costunolide (Cos) can reduce inflammation. However, the role of Cos in obesity cardiomyopathy and its molecular targets remains unknown., We aimed to clarify potential cardioprotective effects and mechanism of Cos against obesity cardiomyopathy., The model of obesity cardiomyopathy was established by feeding mice with a high-fat diet for 24 weeks. Cos at 10 and 20 mg/kg or vehicle (1% CMCNa solution) was administered once every two days via oral gavage from the 17th to 24th week. Body weight, heart weight/tibia length, cardiac function, myocardial injury markers, pathological morphology of the heart, hypertrophic and fibrotic markers, inflammatory factors were assessed. The targets of Cos were predicted through molecular docking. Pull-down assay and biolayer interferometry were used to confirm the target of Cos., Cos effectively reduces obesity-induced cardiomyocyte inflammation, cardiac hypertrophy and fibrosis, thereby improving cardiac function. We confirmed that Cos can interact with TAK1 and inhibit downstream NF-κB pathway activation by blocking the formation of the TAK1/TAB2 complex, thus inhibiting inflammatory cytokine release in cardiomyocytes., Our results demonstrated that Cos significantly improved myocardial remodeling and cardiac dysfunction against obesity cardiomyopathy by reducing myocardial inflammation. Therefore, Cos may serve as a promising therapeutic agent in obesity cardiomyopathy.
ISSN	0944-7113
卷号	108 页码:154523
DOI	10.1016/j.phymed.2022.154523
收录类别	PUBMED
URL	查看原文
PubMed ID	36332385
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/167109
专题	药学院（分析测试中心）_生物有机与药物化学研究中心附属第一医院
作者单位	1.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.; 2.Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, 315000, China.; 3.Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.; 4.Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.; 5.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.; 6.Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. Electronic address: 2855930357@qq.com.; 7.Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; Department of Cardiology and the Key Laboratory of Cardiovascular Disease of Wenzhou, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China; School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang 311399, China. Electronic address: wzmcliangguang@163.com.
第一作者单位	药学院（分析测试中心）_生物有机与药物化学研究中心
第一作者的第一单位	药学院（分析测试中心）_生物有机与药物化学研究中心
推荐引用方式 GB/T 7714	Ye, Bozhi,Chen, Xudong,Chen, Yanghao,et al. Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway.[J]. Phytomedicine : international journal of phytotherapy and phytopharmacology,2022,108:154523.
APA	Ye, Bozhi., Chen, Xudong., Chen, Yanghao., Lin, Wante., Xu, Diyun., ... & Liang, Guang. (2022). Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 108, 154523.
MLA	Ye, Bozhi,et al."Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway.".Phytomedicine : international journal of phytotherapy and phytopharmacology 108(2022):154523.